Overall, tiredness, depression, and poor well-being were the most prevalent moderate-to-severe symptoms across cancer types, reported by 37%, 34%, and 33% of patients, respectively. The median total ...

Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care. Chronic lymphocytic leukemia (CLL) treatment has undergone ...

Vargas, MD discusses how his institution builds a safe learning curve for surgeons adopting the subcostal robotic approach to ...

Nearly 3 years’ follow-up showed cORR 89.8%, median DOR 49.7 months, and median PFS 46.1 months in TKI-naive ROS1+ NSCLC, supporting long-term disease control. Post–ROS1 TKI activity remained ...

David DiBardino, MD, explains how a hafnium compound is being tested alongside chemoradiation and durvalumab to address low ...

The imlunestrant label includes a warning and precaution for embryo-fetal toxicity, and the abemaciclib label includes ...

Oncologists weigh second-line options after IO/TKI failure in metastatic ccRCC, highlighting tolerability, mechanism shifts, and belzutifan’s broader role.

FDA labeling now reports a 49.7-month median DOR in TKI-naive advanced ROS1+ NSCLC from TRUST-I, based on 51-month median ...

Intratumoral delivery emerged to overcome suboptimal systemic immunotherapy response rates in “hot” tumors where escalating systemic dosing is constrained by toxicity. Standardization challenges span ...

AI streamlines oncology workflows, cuts admin burden, and hints at smarter interoperability—linking fragmented records for ...

The FDA has approved Pixclara (floretyrosine F 18), the first FET-PET imaging agent for distinguishing recurrent glioma from treatment-related change. The FDA has approved floretyrosine F 18 (18F-FET; ...

Burnout remains a significant concern among oncologists, with approximately 60% of oncologists reporting burnout, according ...